Insider Transactions in Q2 2025 at Tarsus Pharmaceuticals, Inc. (TARS)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2025
|
Jeffrey S Farrow Officer |
SELL
Open market or private sale
|
Direct |
13,608
-27.05%
|
$544,320
$40.42 P/Share
|
|
Jun 16
2025
|
Jeffrey S Farrow Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,881
+35.66%
|
-
|
|
Jun 16
2025
|
Elizabeth Yeu Lin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,006
-11.56%
|
$41,246
$41.08 P/Share
|
|
Jun 13
2025
|
Elizabeth Yeu Lin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+27.8%
|
-
|
|
Jun 13
2025
|
Andrew D. Goldberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+16.71%
|
-
|
|
Jun 13
2025
|
Bhaskar Chaudhuri Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+27.8%
|
-
|
|
Jun 13
2025
|
William J Phd Link Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+1.93%
|
-
|
|
Jun 13
2025
|
Scott W Morrison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+50.0%
|
-
|
|
Jun 13
2025
|
Wendy L Yarno Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+19.65%
|
-
|
|
Jun 09
2025
|
Aziz Mottiwala Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
17,500
-26.9%
|
$752,500
$43.76 P/Share
|